References

1. Lovenox® [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2006.

2. Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867-873.

3. Büller HR, Davidson BL, Decousus H, et al; MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med.
2003;349:1695-1702.

4. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.

5. Eriksson BI, Bauer KA, Lassen MR, et al; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.

6. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.

7. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet. 2002;359:1715-1720.

8. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hipreplacement surgery: a randomized double-blind trial. Lancet. 2002;359:1721-1726.

9. Surgical Care Improvement Project (SCIP) VTE-1 and VTE-2. Accessed September 19, 2007.

10. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):338S-400S.

11. Eriksson BI, Lassen MR; for the PENTasaccharide in HIp-FRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163:1337-1342.

12. Agnelli G, Bergqvist D, Cohen AT, et al; PEGASUS Investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005;92:1212-1220.

13. Data on File, PEGASUS Study, GlaxoSmithKline.

14. Data on File, MATISSE DVT Study, GlaxoSmithKline.

15. Data on File, MATISSE PE Study, GlaxoSmithKline.

16. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature. 1991;350(suppl 6319):30-33.

17. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation. 1994;89:1449-1468.

18. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest.
2001;119(suppl 1):64S-94S.

19. Nutescu EA, Helgason CM. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors. Pharmacotherapy. 2004;24(7 Pt 2):82S-87S.

20. Weitz JI, Hirsh J. New anticoagulant drugs. Chest.
2001;119(suppl 1):95S-107S.

Please see Important Safety Information and complete Prescribing Information, including BOXED WARNING
regarding epidural and spinal hematomas.